Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.
While there is a long and growing list of FDA approved chemotherapy regimens for multiple myeloma, several of these chemos cause peripheral neuropathy/nerve damage aka CIPN. According to the study linked below 65% of MMers report grade 2-3 PN.
Conventional oncology tells patients that PN goes away once therapy ends but my nerve damage has progressively worsened over the years. I live with increasing numbness. I’ll take numbness over the debilitating burning pain that many myeloma survivors talk about.
The best way to avoid chemotherapy-induced peripheral neuropathy (CIPN) is to prevent this side-effect in the first place. If you already have CIPN, learn more about pain therapy.
The other study linked below cites cannabinoids as nerve pain therapy. The trick with CBD oil is to figure out:
I am both a long-term MM survivor and MM cancer coach. I live an evidence-based, non-toxic, anti-Myeloma lifestyle through nutrition, supplementation, bone health, lifestyle and mind-body therapies.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Are you experiencing chemotherapy-induced nerve damage? Scroll to the bottom of the page, post a question or a comment and I will reply to you ASAP.
“Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients’ health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN…
Overall, 65 % of patients reported grade 2-3 neuropathy according to the ICPNQ…
RESLTS: The psychometric analyses showed a Cronbach’s alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2-3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales.
CONCLUSIONS: CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.
“Treatment options for neuropathic pain have limited efficacy and use is fraught with dose-limiting adverse effects… Exogenous cannabinoids have been demonstrated to be effective in a range of experimental neuropathic pain models, and there is mounting evidence for therapeutic use in human neuropathic pain conditions..”